Novel Conformationally Restricted Amino Acids for Peptidomimetic Drug Design

Our Unique Building Blocks to Perform Far and Wide
18 February 2020
Oleg Lukin
Senior Research Scientist

Conformationally restricted amino acids and peptides in which conformational freedom is substantially reduced by the presence of small rings have obtained a prominent role in drug design and development.1,2

It is postulated that in living organisms these cyclic compounds have reduced metabolism in comparison to their open-chain congeners.3 Indeed, conformationally restricted amino acids have been successfully used in the peptidomimetic drug design as surrogates of proline, a natural amino acid that is found in those secondary structure elements that bring about biological action of peptides.

Many commercial drugs have been designed through the replacement of the proline with its unnatural conformationally restricted analogs. Among these launched drugs are an anticoagulant agent Ximelagatran 14, recently introduced angiotensin-converting enzyme (ACE) inhibitor Zabicipril 25, and a new oral hypoglycemic (anti-diabetic) drug Saxagliptin 3(Figure 1). Conformationally restricted amino acids are also involved in the synthesis of prolyl endopeptidase inhibitors, as exemplified by compound 47 in Figure 1.

 Examples of the use of conformationally restricted amino acids in drug discovery


Several representative conformationally restricted amino acids available from Life Chemicals are depicted below. The full database of the title structures can be provided upon request at

Representative conformationally restricted amino acids by Life Chemicals


  1. (a) Zanuy, D.; Ballano, G.; Jimenez, A. I.; Casanovas, J.; Haspel, N.; Cativie, C.; Curco, D.; Nussinov, R.; Aleman, C. J. Chem. Inf. Model. 200949, 1623-1629. (b) Komarov, I. V.; Grigorenko, A. O.; Turov, A. V.; Khilya. V. P. Russ. Chem. Rev200473, 785–810.
  2. Lasota, A.; Fraczak, O.; Lesniak, A.; Muchowska, A.; Lipkowski, A. W.; Nowakowski, M.; Ejchart, A.; Olma, A. J. Pept. Sci201521, 120-125.
  3. Komarov, I. V.; Grygorenko, O. O.; Radchenko, D. S.; Artamonov, O. S.; Kostyuk, A. N.; Tolmachev, A. N. Chemistry Today 200624, 22-23.
  4. Gustafsson, D.; Bylund, R.; Antonsson, T.; Nilsson, I.; Nyström, J.-E.; Eriksson, U.; Bredberg, U.; Teger-Nilsson, A.-C. Nature Reviews/Drug Discovery 20043, 649-659.
  5. Vincent, M.; Pascard, C.; Cesario, M.; Rémond, G.; Bouchet, J.-P.; Charton, Y.; Laubie. M. Tetrahedron Lett199233, 7369.
18 February 2020, 17:18 Oleg Lukin Building Blocks

Comments ()

    This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. By using our website, you accept our conditions of use of cookies to track data and create content (including advertising) based on your interest. Accept